Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 73,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'catslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 73,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/vaccine-against-dengue-to-be-tested-in-india-kounteya-sinha-18177/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/vaccine-against-dengue-to-be-tested-in-india-kounteya-sinha-18177/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'catslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 73
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 74,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'artileslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 74,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/vaccine-against-dengue-to-be-tested-in-india-kounteya-sinha-18177/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/vaccine-against-dengue-to-be-tested-in-india-kounteya-sinha-18177/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'artileslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 74
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Code Context
            if (Configure::read('debug')) {

                trigger_error($message, E_USER_WARNING);

            } else {
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f105bc7fc66-trace').style.display = (document.getElementById('cakeErr67f105bc7fc66-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f105bc7fc66-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f105bc7fc66-code').style.display = (document.getElementById('cakeErr67f105bc7fc66-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f105bc7fc66-context').style.display = (document.getElementById('cakeErr67f105bc7fc66-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f105bc7fc66-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f105bc7fc66-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 18048,
		&#039;title&#039; =&gt; &#039;Vaccine against dengue to be tested in India -Kounteya Sinha&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div style=&quot;text-align: justify&quot;&gt;
-The Times of India
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;em&gt;PARIS:&lt;/em&gt; The world&#039;s most effective vaccine candidate against dengue is all set for trials in India and if all goes to plan, the vaccine will be available globally by 2015.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The vaccine will be tested on 120-odd adults in the beginning, the results of which should be available by 2013. Thereafter, a largescale study on children &amp;mdash; the main target group &amp;mdash; will be undertaken.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
In an exclusive interview, French pharma giant Sanofi Pasteur&#039;s CEO Christopher Viehbacher told TOI, &amp;quot;Sites for the vaccine&#039;s final trials will stretch from Thailand to India as this vaccine has to work on populations across countries. We will test it in India soon.&amp;quot;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Dr Jean Lang, head of the vaccine&#039;s R&amp;amp;D programme, added, &amp;quot;The drug controller general of India has asked us to conduct phase II safety trials on adults first, then on children. It will help us get licence to market the vaccine in India faster if it has been tested on the Indian population and is found safe and effective.&amp;quot;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;em&gt;Vaccine fights 3 of 4 dengue strains&lt;/em&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Even the world&#039;s most effective dengue vaccine candidate, set for trials in India soon, will not be able to counter all virus strains, early tests have showed.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
There is currently no vaccine to protect against dengue, and efforts to develop one have been hamstrung since four viruses (known as DENV 1, 2, 3 and 4) cause the disease. Researchers in France and Thailand recently announced that the vaccine under trials &amp;mdash; French pharma giant Sanofi Pasteur&#039;s CYD-TDV &amp;mdash; was tested for its effectiveness on a group of 4,002 schoolchildren in Thailand, aged four to eleven. Secondary tests showed that the vaccine was effective against DENV 1, 3 and 4 but not on DENV 2, which appeared to be resistant. The vaccine showed a 60-90% protection rate against three main virus strains (DENV 1, 3 and 4).
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&amp;quot;We are trying to find out why the vaccine wasn&#039;t very effective against the strain type 2,&amp;quot; said Sanofi&#039;s global R&amp;amp;D president Dr Elias Zerhouni. &amp;quot;We are also working on designing a separate vaccine to combat type 2 and a separate vaccine effective against the other three strains of dengue.&amp;quot;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Sources told TOI that a high-level meeting was held between scientists from Sanofi&#039;s dengue vaccine team and Indian experts, including former director general of the Indian Council of Medical Research Dr N K Ganguly, in New Delhi to discuss the India trials which will begins soon.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Dr A C Dhariwal, head of India&#039;s National Vector Borne Disease Control Programme, said, &amp;quot;It is the strain 2 that causes dengue hemorrhagic fever which is life-threatening. And this vaccine does not protect against this strain.&amp;quot; Of the estimated 230 million people infected annually, two million &amp;mdash; mostly children &amp;mdash; develop dengue hemorrhagic fever (DHF), a severe form of the disease. According to Jean Lang, head of the vaccine&#039;s R&amp;amp;D programme, largescale phase III clinical studies of the vaccine are presently under way on 31,000 adults and children in 10 countries &amp;mdash; Mexico, Colombia, Honduras, Puerto Rico, Brazil, the Philippines, Vietnam, Malaysia, Indonesia and Thailand.&amp;nbsp;
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Times of India, 19 November, 2012, http://timesofindia.indiatimes.com/home/science/Vaccine-against-dengue-to-be-tested-in-India/articleshow/17274153.cms&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;vaccine-against-dengue-to-be-tested-in-india-kounteya-sinha-18177&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 18177,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 18048,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Vaccine against dengue to be tested in India -Kounteya Sinha&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;dengue,Health,medicines&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Times of India





PARIS: The world&#039;s most effective vaccine candidate against dengue is all set for trials in India and if all goes to plan, the vaccine will be available globally by 2015.





The vaccine will be tested on 120-odd adults...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div style=&quot;text-align: justify&quot;&gt;-The Times of India&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;em&gt;PARIS:&lt;/em&gt; The world&#039;s most effective vaccine candidate against dengue is all set for trials in India and if all goes to plan, the vaccine will be available globally by 2015.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The vaccine will be tested on 120-odd adults in the beginning, the results of which should be available by 2013. Thereafter, a largescale study on children &amp;mdash; the main target group &amp;mdash; will be undertaken.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;In an exclusive interview, French pharma giant Sanofi Pasteur&#039;s CEO Christopher Viehbacher told TOI, &amp;quot;Sites for the vaccine&#039;s final trials will stretch from Thailand to India as this vaccine has to work on populations across countries. We will test it in India soon.&amp;quot;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Dr Jean Lang, head of the vaccine&#039;s R&amp;amp;D programme, added, &amp;quot;The drug controller general of India has asked us to conduct phase II safety trials on adults first, then on children. It will help us get licence to market the vaccine in India faster if it has been tested on the Indian population and is found safe and effective.&amp;quot;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;em&gt;Vaccine fights 3 of 4 dengue strains&lt;/em&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Even the world&#039;s most effective dengue vaccine candidate, set for trials in India soon, will not be able to counter all virus strains, early tests have showed.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;There is currently no vaccine to protect against dengue, and efforts to develop one have been hamstrung since four viruses (known as DENV 1, 2, 3 and 4) cause the disease. Researchers in France and Thailand recently announced that the vaccine under trials &amp;mdash; French pharma giant Sanofi Pasteur&#039;s CYD-TDV &amp;mdash; was tested for its effectiveness on a group of 4,002 schoolchildren in Thailand, aged four to eleven. Secondary tests showed that the vaccine was effective against DENV 1, 3 and 4 but not on DENV 2, which appeared to be resistant. The vaccine showed a 60-90% protection rate against three main virus strains (DENV 1, 3 and 4).&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&amp;quot;We are trying to find out why the vaccine wasn&#039;t very effective against the strain type 2,&amp;quot; said Sanofi&#039;s global R&amp;amp;D president Dr Elias Zerhouni. &amp;quot;We are also working on designing a separate vaccine to combat type 2 and a separate vaccine effective against the other three strains of dengue.&amp;quot;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Sources told TOI that a high-level meeting was held between scientists from Sanofi&#039;s dengue vaccine team and Indian experts, including former director general of the Indian Council of Medical Research Dr N K Ganguly, in New Delhi to discuss the India trials which will begins soon.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Dr A C Dhariwal, head of India&#039;s National Vector Borne Disease Control Programme, said, &amp;quot;It is the strain 2 that causes dengue hemorrhagic fever which is life-threatening. And this vaccine does not protect against this strain.&amp;quot; Of the estimated 230 million people infected annually, two million &amp;mdash; mostly children &amp;mdash; develop dengue hemorrhagic fever (DHF), a severe form of the disease. According to Jean Lang, head of the vaccine&#039;s R&amp;amp;D programme, largescale phase III clinical studies of the vaccine are presently under way on 31,000 adults and children in 10 countries &amp;mdash; Mexico, Colombia, Honduras, Puerto Rico, Brazil, the Philippines, Vietnam, Malaysia, Indonesia and Thailand.&amp;nbsp;&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 18048,
	&#039;title&#039; =&gt; &#039;Vaccine against dengue to be tested in India -Kounteya Sinha&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div style=&quot;text-align: justify&quot;&gt;
-The Times of India
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;em&gt;PARIS:&lt;/em&gt; The world&#039;s most effective vaccine candidate against dengue is all set for trials in India and if all goes to plan, the vaccine will be available globally by 2015.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The vaccine will be tested on 120-odd adults in the beginning, the results of which should be available by 2013. Thereafter, a largescale study on children &amp;mdash; the main target group &amp;mdash; will be undertaken.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
In an exclusive interview, French pharma giant Sanofi Pasteur&#039;s CEO Christopher Viehbacher told TOI, &amp;quot;Sites for the vaccine&#039;s final trials will stretch from Thailand to India as this vaccine has to work on populations across countries. We will test it in India soon.&amp;quot;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Dr Jean Lang, head of the vaccine&#039;s R&amp;amp;D programme, added, &amp;quot;The drug controller general of India has asked us to conduct phase II safety trials on adults first, then on children. It will help us get licence to market the vaccine in India faster if it has been tested on the Indian population and is found safe and effective.&amp;quot;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;em&gt;Vaccine fights 3 of 4 dengue strains&lt;/em&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Even the world&#039;s most effective dengue vaccine candidate, set for trials in India soon, will not be able to counter all virus strains, early tests have showed.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
There is currently no vaccine to protect against dengue, and efforts to develop one have been hamstrung since four viruses (known as DENV 1, 2, 3 and 4) cause the disease. Researchers in France and Thailand recently announced that the vaccine under trials &amp;mdash; French pharma giant Sanofi Pasteur&#039;s CYD-TDV &amp;mdash; was tested for its effectiveness on a group of 4,002 schoolchildren in Thailand, aged four to eleven. Secondary tests showed that the vaccine was effective against DENV 1, 3 and 4 but not on DENV 2, which appeared to be resistant. The vaccine showed a 60-90% protection rate against three main virus strains (DENV 1, 3 and 4).
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&amp;quot;We are trying to find out why the vaccine wasn&#039;t very effective against the strain type 2,&amp;quot; said Sanofi&#039;s global R&amp;amp;D president Dr Elias Zerhouni. &amp;quot;We are also working on designing a separate vaccine to combat type 2 and a separate vaccine effective against the other three strains of dengue.&amp;quot;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Sources told TOI that a high-level meeting was held between scientists from Sanofi&#039;s dengue vaccine team and Indian experts, including former director general of the Indian Council of Medical Research Dr N K Ganguly, in New Delhi to discuss the India trials which will begins soon.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Dr A C Dhariwal, head of India&#039;s National Vector Borne Disease Control Programme, said, &amp;quot;It is the strain 2 that causes dengue hemorrhagic fever which is life-threatening. And this vaccine does not protect against this strain.&amp;quot; Of the estimated 230 million people infected annually, two million &amp;mdash; mostly children &amp;mdash; develop dengue hemorrhagic fever (DHF), a severe form of the disease. According to Jean Lang, head of the vaccine&#039;s R&amp;amp;D programme, largescale phase III clinical studies of the vaccine are presently under way on 31,000 adults and children in 10 countries &amp;mdash; Mexico, Colombia, Honduras, Puerto Rico, Brazil, the Philippines, Vietnam, Malaysia, Indonesia and Thailand.&amp;nbsp;
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Times of India, 19 November, 2012, http://timesofindia.indiatimes.com/home/science/Vaccine-against-dengue-to-be-tested-in-India/articleshow/17274153.cms&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;vaccine-against-dengue-to-be-tested-in-india-kounteya-sinha-18177&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 18177,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 18048
$metaTitle = &#039;LATEST NEWS UPDATES | Vaccine against dengue to be tested in India -Kounteya Sinha&#039;
$metaKeywords = &#039;dengue,Health,medicines&#039;
$metaDesc = &#039;
-The Times of India





PARIS: The world&#039;s most effective vaccine candidate against dengue is all set for trials in India and if all goes to plan, the vaccine will be available globally by 2015.





The vaccine will be tested on 120-odd adults...&#039;
$disp = &#039;&lt;div style=&quot;text-align: justify&quot;&gt;-The Times of India&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;em&gt;PARIS:&lt;/em&gt; The world&#039;s most effective vaccine candidate against dengue is all set for trials in India and if all goes to plan, the vaccine will be available globally by 2015.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The vaccine will be tested on 120-odd adults in the beginning, the results of which should be available by 2013. Thereafter, a largescale study on children &amp;mdash; the main target group &amp;mdash; will be undertaken.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;In an exclusive interview, French pharma giant Sanofi Pasteur&#039;s CEO Christopher Viehbacher told TOI, &amp;quot;Sites for the vaccine&#039;s final trials will stretch from Thailand to India as this vaccine has to work on populations across countries. We will test it in India soon.&amp;quot;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Dr Jean Lang, head of the vaccine&#039;s R&amp;amp;D programme, added, &amp;quot;The drug controller general of India has asked us to conduct phase II safety trials on adults first, then on children. It will help us get licence to market the vaccine in India faster if it has been tested on the Indian population and is found safe and effective.&amp;quot;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;em&gt;Vaccine fights 3 of 4 dengue strains&lt;/em&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Even the world&#039;s most effective dengue vaccine candidate, set for trials in India soon, will not be able to counter all virus strains, early tests have showed.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;There is currently no vaccine to protect against dengue, and efforts to develop one have been hamstrung since four viruses (known as DENV 1, 2, 3 and 4) cause the disease. Researchers in France and Thailand recently announced that the vaccine under trials &amp;mdash; French pharma giant Sanofi Pasteur&#039;s CYD-TDV &amp;mdash; was tested for its effectiveness on a group of 4,002 schoolchildren in Thailand, aged four to eleven. Secondary tests showed that the vaccine was effective against DENV 1, 3 and 4 but not on DENV 2, which appeared to be resistant. The vaccine showed a 60-90% protection rate against three main virus strains (DENV 1, 3 and 4).&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&amp;quot;We are trying to find out why the vaccine wasn&#039;t very effective against the strain type 2,&amp;quot; said Sanofi&#039;s global R&amp;amp;D president Dr Elias Zerhouni. &amp;quot;We are also working on designing a separate vaccine to combat type 2 and a separate vaccine effective against the other three strains of dengue.&amp;quot;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Sources told TOI that a high-level meeting was held between scientists from Sanofi&#039;s dengue vaccine team and Indian experts, including former director general of the Indian Council of Medical Research Dr N K Ganguly, in New Delhi to discuss the India trials which will begins soon.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Dr A C Dhariwal, head of India&#039;s National Vector Borne Disease Control Programme, said, &amp;quot;It is the strain 2 that causes dengue hemorrhagic fever which is life-threatening. And this vaccine does not protect against this strain.&amp;quot; Of the estimated 230 million people infected annually, two million &amp;mdash; mostly children &amp;mdash; develop dengue hemorrhagic fever (DHF), a severe form of the disease. According to Jean Lang, head of the vaccine&#039;s R&amp;amp;D programme, largescale phase III clinical studies of the vaccine are presently under way on 31,000 adults and children in 10 countries &amp;mdash; Mexico, Colombia, Honduras, Puerto Rico, Brazil, the Philippines, Vietnam, Malaysia, Indonesia and Thailand.&amp;nbsp;&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/vaccine-against-dengue-to-be-tested-in-india-kounteya-sinha-18177.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Vaccine against dengue to be tested in India -Kounteya Sinha | Im4change.org</title>
    <meta name="description" content="
-The Times of India





PARIS: The world's most effective vaccine candidate against dengue is all set for trials in India and if all goes to plan, the vaccine will be available globally by 2015.





The vaccine will be tested on 120-odd adults..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Vaccine against dengue to be tested in India -Kounteya Sinha</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div style="text-align: justify">-The Times of India</div><div style="text-align: justify"><br /></div><div style="text-align: justify"><em>PARIS:</em> The world's most effective vaccine candidate against dengue is all set for trials in India and if all goes to plan, the vaccine will be available globally by 2015.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The vaccine will be tested on 120-odd adults in the beginning, the results of which should be available by 2013. Thereafter, a largescale study on children &mdash; the main target group &mdash; will be undertaken.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">In an exclusive interview, French pharma giant Sanofi Pasteur's CEO Christopher Viehbacher told TOI, &quot;Sites for the vaccine's final trials will stretch from Thailand to India as this vaccine has to work on populations across countries. We will test it in India soon.&quot;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">Dr Jean Lang, head of the vaccine's R&amp;D programme, added, &quot;The drug controller general of India has asked us to conduct phase II safety trials on adults first, then on children. It will help us get licence to market the vaccine in India faster if it has been tested on the Indian population and is found safe and effective.&quot;</div><div style="text-align: justify"><br /></div><div style="text-align: justify"><em>Vaccine fights 3 of 4 dengue strains</em></div><div style="text-align: justify"><br /></div><div style="text-align: justify">Even the world's most effective dengue vaccine candidate, set for trials in India soon, will not be able to counter all virus strains, early tests have showed.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">There is currently no vaccine to protect against dengue, and efforts to develop one have been hamstrung since four viruses (known as DENV 1, 2, 3 and 4) cause the disease. Researchers in France and Thailand recently announced that the vaccine under trials &mdash; French pharma giant Sanofi Pasteur's CYD-TDV &mdash; was tested for its effectiveness on a group of 4,002 schoolchildren in Thailand, aged four to eleven. Secondary tests showed that the vaccine was effective against DENV 1, 3 and 4 but not on DENV 2, which appeared to be resistant. The vaccine showed a 60-90% protection rate against three main virus strains (DENV 1, 3 and 4).</div><div style="text-align: justify"><br /></div><div style="text-align: justify">&quot;We are trying to find out why the vaccine wasn't very effective against the strain type 2,&quot; said Sanofi's global R&amp;D president Dr Elias Zerhouni. &quot;We are also working on designing a separate vaccine to combat type 2 and a separate vaccine effective against the other three strains of dengue.&quot;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">Sources told TOI that a high-level meeting was held between scientists from Sanofi's dengue vaccine team and Indian experts, including former director general of the Indian Council of Medical Research Dr N K Ganguly, in New Delhi to discuss the India trials which will begins soon.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">Dr A C Dhariwal, head of India's National Vector Borne Disease Control Programme, said, &quot;It is the strain 2 that causes dengue hemorrhagic fever which is life-threatening. And this vaccine does not protect against this strain.&quot; Of the estimated 230 million people infected annually, two million &mdash; mostly children &mdash; develop dengue hemorrhagic fever (DHF), a severe form of the disease. According to Jean Lang, head of the vaccine's R&amp;D programme, largescale phase III clinical studies of the vaccine are presently under way on 31,000 adults and children in 10 countries &mdash; Mexico, Colombia, Honduras, Puerto Rico, Brazil, the Philippines, Vietnam, Malaysia, Indonesia and Thailand.&nbsp;</div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$maxBufferLength = (int) 8192
$file = '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php'
$line = (int) 853
$message = 'Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853'
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 48
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Code Context
            $response->getStatusCode(),

            ($reasonPhrase ? ' ' . $reasonPhrase : '')

        ));
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f105bc7fc66-trace').style.display = (document.getElementById('cakeErr67f105bc7fc66-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f105bc7fc66-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f105bc7fc66-code').style.display = (document.getElementById('cakeErr67f105bc7fc66-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f105bc7fc66-context').style.display = (document.getElementById('cakeErr67f105bc7fc66-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f105bc7fc66-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f105bc7fc66-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 18048,
		&#039;title&#039; =&gt; &#039;Vaccine against dengue to be tested in India -Kounteya Sinha&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div style=&quot;text-align: justify&quot;&gt;
-The Times of India
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;em&gt;PARIS:&lt;/em&gt; The world&#039;s most effective vaccine candidate against dengue is all set for trials in India and if all goes to plan, the vaccine will be available globally by 2015.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The vaccine will be tested on 120-odd adults in the beginning, the results of which should be available by 2013. Thereafter, a largescale study on children &amp;mdash; the main target group &amp;mdash; will be undertaken.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
In an exclusive interview, French pharma giant Sanofi Pasteur&#039;s CEO Christopher Viehbacher told TOI, &amp;quot;Sites for the vaccine&#039;s final trials will stretch from Thailand to India as this vaccine has to work on populations across countries. We will test it in India soon.&amp;quot;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Dr Jean Lang, head of the vaccine&#039;s R&amp;amp;D programme, added, &amp;quot;The drug controller general of India has asked us to conduct phase II safety trials on adults first, then on children. It will help us get licence to market the vaccine in India faster if it has been tested on the Indian population and is found safe and effective.&amp;quot;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;em&gt;Vaccine fights 3 of 4 dengue strains&lt;/em&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Even the world&#039;s most effective dengue vaccine candidate, set for trials in India soon, will not be able to counter all virus strains, early tests have showed.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
There is currently no vaccine to protect against dengue, and efforts to develop one have been hamstrung since four viruses (known as DENV 1, 2, 3 and 4) cause the disease. Researchers in France and Thailand recently announced that the vaccine under trials &amp;mdash; French pharma giant Sanofi Pasteur&#039;s CYD-TDV &amp;mdash; was tested for its effectiveness on a group of 4,002 schoolchildren in Thailand, aged four to eleven. Secondary tests showed that the vaccine was effective against DENV 1, 3 and 4 but not on DENV 2, which appeared to be resistant. The vaccine showed a 60-90% protection rate against three main virus strains (DENV 1, 3 and 4).
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&amp;quot;We are trying to find out why the vaccine wasn&#039;t very effective against the strain type 2,&amp;quot; said Sanofi&#039;s global R&amp;amp;D president Dr Elias Zerhouni. &amp;quot;We are also working on designing a separate vaccine to combat type 2 and a separate vaccine effective against the other three strains of dengue.&amp;quot;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Sources told TOI that a high-level meeting was held between scientists from Sanofi&#039;s dengue vaccine team and Indian experts, including former director general of the Indian Council of Medical Research Dr N K Ganguly, in New Delhi to discuss the India trials which will begins soon.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Dr A C Dhariwal, head of India&#039;s National Vector Borne Disease Control Programme, said, &amp;quot;It is the strain 2 that causes dengue hemorrhagic fever which is life-threatening. And this vaccine does not protect against this strain.&amp;quot; Of the estimated 230 million people infected annually, two million &amp;mdash; mostly children &amp;mdash; develop dengue hemorrhagic fever (DHF), a severe form of the disease. According to Jean Lang, head of the vaccine&#039;s R&amp;amp;D programme, largescale phase III clinical studies of the vaccine are presently under way on 31,000 adults and children in 10 countries &amp;mdash; Mexico, Colombia, Honduras, Puerto Rico, Brazil, the Philippines, Vietnam, Malaysia, Indonesia and Thailand.&amp;nbsp;
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Times of India, 19 November, 2012, http://timesofindia.indiatimes.com/home/science/Vaccine-against-dengue-to-be-tested-in-India/articleshow/17274153.cms&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;vaccine-against-dengue-to-be-tested-in-india-kounteya-sinha-18177&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 18177,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 18048,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Vaccine against dengue to be tested in India -Kounteya Sinha&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;dengue,Health,medicines&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Times of India





PARIS: The world&#039;s most effective vaccine candidate against dengue is all set for trials in India and if all goes to plan, the vaccine will be available globally by 2015.





The vaccine will be tested on 120-odd adults...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div style=&quot;text-align: justify&quot;&gt;-The Times of India&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;em&gt;PARIS:&lt;/em&gt; The world&#039;s most effective vaccine candidate against dengue is all set for trials in India and if all goes to plan, the vaccine will be available globally by 2015.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The vaccine will be tested on 120-odd adults in the beginning, the results of which should be available by 2013. Thereafter, a largescale study on children &amp;mdash; the main target group &amp;mdash; will be undertaken.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;In an exclusive interview, French pharma giant Sanofi Pasteur&#039;s CEO Christopher Viehbacher told TOI, &amp;quot;Sites for the vaccine&#039;s final trials will stretch from Thailand to India as this vaccine has to work on populations across countries. We will test it in India soon.&amp;quot;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Dr Jean Lang, head of the vaccine&#039;s R&amp;amp;D programme, added, &amp;quot;The drug controller general of India has asked us to conduct phase II safety trials on adults first, then on children. It will help us get licence to market the vaccine in India faster if it has been tested on the Indian population and is found safe and effective.&amp;quot;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;em&gt;Vaccine fights 3 of 4 dengue strains&lt;/em&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Even the world&#039;s most effective dengue vaccine candidate, set for trials in India soon, will not be able to counter all virus strains, early tests have showed.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;There is currently no vaccine to protect against dengue, and efforts to develop one have been hamstrung since four viruses (known as DENV 1, 2, 3 and 4) cause the disease. Researchers in France and Thailand recently announced that the vaccine under trials &amp;mdash; French pharma giant Sanofi Pasteur&#039;s CYD-TDV &amp;mdash; was tested for its effectiveness on a group of 4,002 schoolchildren in Thailand, aged four to eleven. Secondary tests showed that the vaccine was effective against DENV 1, 3 and 4 but not on DENV 2, which appeared to be resistant. The vaccine showed a 60-90% protection rate against three main virus strains (DENV 1, 3 and 4).&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&amp;quot;We are trying to find out why the vaccine wasn&#039;t very effective against the strain type 2,&amp;quot; said Sanofi&#039;s global R&amp;amp;D president Dr Elias Zerhouni. &amp;quot;We are also working on designing a separate vaccine to combat type 2 and a separate vaccine effective against the other three strains of dengue.&amp;quot;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Sources told TOI that a high-level meeting was held between scientists from Sanofi&#039;s dengue vaccine team and Indian experts, including former director general of the Indian Council of Medical Research Dr N K Ganguly, in New Delhi to discuss the India trials which will begins soon.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Dr A C Dhariwal, head of India&#039;s National Vector Borne Disease Control Programme, said, &amp;quot;It is the strain 2 that causes dengue hemorrhagic fever which is life-threatening. And this vaccine does not protect against this strain.&amp;quot; Of the estimated 230 million people infected annually, two million &amp;mdash; mostly children &amp;mdash; develop dengue hemorrhagic fever (DHF), a severe form of the disease. According to Jean Lang, head of the vaccine&#039;s R&amp;amp;D programme, largescale phase III clinical studies of the vaccine are presently under way on 31,000 adults and children in 10 countries &amp;mdash; Mexico, Colombia, Honduras, Puerto Rico, Brazil, the Philippines, Vietnam, Malaysia, Indonesia and Thailand.&amp;nbsp;&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 18048,
	&#039;title&#039; =&gt; &#039;Vaccine against dengue to be tested in India -Kounteya Sinha&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div style=&quot;text-align: justify&quot;&gt;
-The Times of India
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;em&gt;PARIS:&lt;/em&gt; The world&#039;s most effective vaccine candidate against dengue is all set for trials in India and if all goes to plan, the vaccine will be available globally by 2015.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The vaccine will be tested on 120-odd adults in the beginning, the results of which should be available by 2013. Thereafter, a largescale study on children &amp;mdash; the main target group &amp;mdash; will be undertaken.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
In an exclusive interview, French pharma giant Sanofi Pasteur&#039;s CEO Christopher Viehbacher told TOI, &amp;quot;Sites for the vaccine&#039;s final trials will stretch from Thailand to India as this vaccine has to work on populations across countries. We will test it in India soon.&amp;quot;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Dr Jean Lang, head of the vaccine&#039;s R&amp;amp;D programme, added, &amp;quot;The drug controller general of India has asked us to conduct phase II safety trials on adults first, then on children. It will help us get licence to market the vaccine in India faster if it has been tested on the Indian population and is found safe and effective.&amp;quot;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;em&gt;Vaccine fights 3 of 4 dengue strains&lt;/em&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Even the world&#039;s most effective dengue vaccine candidate, set for trials in India soon, will not be able to counter all virus strains, early tests have showed.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
There is currently no vaccine to protect against dengue, and efforts to develop one have been hamstrung since four viruses (known as DENV 1, 2, 3 and 4) cause the disease. Researchers in France and Thailand recently announced that the vaccine under trials &amp;mdash; French pharma giant Sanofi Pasteur&#039;s CYD-TDV &amp;mdash; was tested for its effectiveness on a group of 4,002 schoolchildren in Thailand, aged four to eleven. Secondary tests showed that the vaccine was effective against DENV 1, 3 and 4 but not on DENV 2, which appeared to be resistant. The vaccine showed a 60-90% protection rate against three main virus strains (DENV 1, 3 and 4).
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&amp;quot;We are trying to find out why the vaccine wasn&#039;t very effective against the strain type 2,&amp;quot; said Sanofi&#039;s global R&amp;amp;D president Dr Elias Zerhouni. &amp;quot;We are also working on designing a separate vaccine to combat type 2 and a separate vaccine effective against the other three strains of dengue.&amp;quot;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Sources told TOI that a high-level meeting was held between scientists from Sanofi&#039;s dengue vaccine team and Indian experts, including former director general of the Indian Council of Medical Research Dr N K Ganguly, in New Delhi to discuss the India trials which will begins soon.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Dr A C Dhariwal, head of India&#039;s National Vector Borne Disease Control Programme, said, &amp;quot;It is the strain 2 that causes dengue hemorrhagic fever which is life-threatening. And this vaccine does not protect against this strain.&amp;quot; Of the estimated 230 million people infected annually, two million &amp;mdash; mostly children &amp;mdash; develop dengue hemorrhagic fever (DHF), a severe form of the disease. According to Jean Lang, head of the vaccine&#039;s R&amp;amp;D programme, largescale phase III clinical studies of the vaccine are presently under way on 31,000 adults and children in 10 countries &amp;mdash; Mexico, Colombia, Honduras, Puerto Rico, Brazil, the Philippines, Vietnam, Malaysia, Indonesia and Thailand.&amp;nbsp;
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Times of India, 19 November, 2012, http://timesofindia.indiatimes.com/home/science/Vaccine-against-dengue-to-be-tested-in-India/articleshow/17274153.cms&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;vaccine-against-dengue-to-be-tested-in-india-kounteya-sinha-18177&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 18177,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 18048
$metaTitle = &#039;LATEST NEWS UPDATES | Vaccine against dengue to be tested in India -Kounteya Sinha&#039;
$metaKeywords = &#039;dengue,Health,medicines&#039;
$metaDesc = &#039;
-The Times of India





PARIS: The world&#039;s most effective vaccine candidate against dengue is all set for trials in India and if all goes to plan, the vaccine will be available globally by 2015.





The vaccine will be tested on 120-odd adults...&#039;
$disp = &#039;&lt;div style=&quot;text-align: justify&quot;&gt;-The Times of India&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;em&gt;PARIS:&lt;/em&gt; The world&#039;s most effective vaccine candidate against dengue is all set for trials in India and if all goes to plan, the vaccine will be available globally by 2015.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The vaccine will be tested on 120-odd adults in the beginning, the results of which should be available by 2013. Thereafter, a largescale study on children &amp;mdash; the main target group &amp;mdash; will be undertaken.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;In an exclusive interview, French pharma giant Sanofi Pasteur&#039;s CEO Christopher Viehbacher told TOI, &amp;quot;Sites for the vaccine&#039;s final trials will stretch from Thailand to India as this vaccine has to work on populations across countries. We will test it in India soon.&amp;quot;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Dr Jean Lang, head of the vaccine&#039;s R&amp;amp;D programme, added, &amp;quot;The drug controller general of India has asked us to conduct phase II safety trials on adults first, then on children. It will help us get licence to market the vaccine in India faster if it has been tested on the Indian population and is found safe and effective.&amp;quot;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;em&gt;Vaccine fights 3 of 4 dengue strains&lt;/em&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Even the world&#039;s most effective dengue vaccine candidate, set for trials in India soon, will not be able to counter all virus strains, early tests have showed.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;There is currently no vaccine to protect against dengue, and efforts to develop one have been hamstrung since four viruses (known as DENV 1, 2, 3 and 4) cause the disease. Researchers in France and Thailand recently announced that the vaccine under trials &amp;mdash; French pharma giant Sanofi Pasteur&#039;s CYD-TDV &amp;mdash; was tested for its effectiveness on a group of 4,002 schoolchildren in Thailand, aged four to eleven. Secondary tests showed that the vaccine was effective against DENV 1, 3 and 4 but not on DENV 2, which appeared to be resistant. The vaccine showed a 60-90% protection rate against three main virus strains (DENV 1, 3 and 4).&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&amp;quot;We are trying to find out why the vaccine wasn&#039;t very effective against the strain type 2,&amp;quot; said Sanofi&#039;s global R&amp;amp;D president Dr Elias Zerhouni. &amp;quot;We are also working on designing a separate vaccine to combat type 2 and a separate vaccine effective against the other three strains of dengue.&amp;quot;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Sources told TOI that a high-level meeting was held between scientists from Sanofi&#039;s dengue vaccine team and Indian experts, including former director general of the Indian Council of Medical Research Dr N K Ganguly, in New Delhi to discuss the India trials which will begins soon.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Dr A C Dhariwal, head of India&#039;s National Vector Borne Disease Control Programme, said, &amp;quot;It is the strain 2 that causes dengue hemorrhagic fever which is life-threatening. And this vaccine does not protect against this strain.&amp;quot; Of the estimated 230 million people infected annually, two million &amp;mdash; mostly children &amp;mdash; develop dengue hemorrhagic fever (DHF), a severe form of the disease. According to Jean Lang, head of the vaccine&#039;s R&amp;amp;D programme, largescale phase III clinical studies of the vaccine are presently under way on 31,000 adults and children in 10 countries &amp;mdash; Mexico, Colombia, Honduras, Puerto Rico, Brazil, the Philippines, Vietnam, Malaysia, Indonesia and Thailand.&amp;nbsp;&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/vaccine-against-dengue-to-be-tested-in-india-kounteya-sinha-18177.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Vaccine against dengue to be tested in India -Kounteya Sinha | Im4change.org</title>
    <meta name="description" content="
-The Times of India





PARIS: The world's most effective vaccine candidate against dengue is all set for trials in India and if all goes to plan, the vaccine will be available globally by 2015.





The vaccine will be tested on 120-odd adults..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Vaccine against dengue to be tested in India -Kounteya Sinha</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div style="text-align: justify">-The Times of India</div><div style="text-align: justify"><br /></div><div style="text-align: justify"><em>PARIS:</em> The world's most effective vaccine candidate against dengue is all set for trials in India and if all goes to plan, the vaccine will be available globally by 2015.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The vaccine will be tested on 120-odd adults in the beginning, the results of which should be available by 2013. Thereafter, a largescale study on children &mdash; the main target group &mdash; will be undertaken.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">In an exclusive interview, French pharma giant Sanofi Pasteur's CEO Christopher Viehbacher told TOI, &quot;Sites for the vaccine's final trials will stretch from Thailand to India as this vaccine has to work on populations across countries. We will test it in India soon.&quot;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">Dr Jean Lang, head of the vaccine's R&amp;D programme, added, &quot;The drug controller general of India has asked us to conduct phase II safety trials on adults first, then on children. It will help us get licence to market the vaccine in India faster if it has been tested on the Indian population and is found safe and effective.&quot;</div><div style="text-align: justify"><br /></div><div style="text-align: justify"><em>Vaccine fights 3 of 4 dengue strains</em></div><div style="text-align: justify"><br /></div><div style="text-align: justify">Even the world's most effective dengue vaccine candidate, set for trials in India soon, will not be able to counter all virus strains, early tests have showed.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">There is currently no vaccine to protect against dengue, and efforts to develop one have been hamstrung since four viruses (known as DENV 1, 2, 3 and 4) cause the disease. Researchers in France and Thailand recently announced that the vaccine under trials &mdash; French pharma giant Sanofi Pasteur's CYD-TDV &mdash; was tested for its effectiveness on a group of 4,002 schoolchildren in Thailand, aged four to eleven. Secondary tests showed that the vaccine was effective against DENV 1, 3 and 4 but not on DENV 2, which appeared to be resistant. The vaccine showed a 60-90% protection rate against three main virus strains (DENV 1, 3 and 4).</div><div style="text-align: justify"><br /></div><div style="text-align: justify">&quot;We are trying to find out why the vaccine wasn't very effective against the strain type 2,&quot; said Sanofi's global R&amp;D president Dr Elias Zerhouni. &quot;We are also working on designing a separate vaccine to combat type 2 and a separate vaccine effective against the other three strains of dengue.&quot;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">Sources told TOI that a high-level meeting was held between scientists from Sanofi's dengue vaccine team and Indian experts, including former director general of the Indian Council of Medical Research Dr N K Ganguly, in New Delhi to discuss the India trials which will begins soon.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">Dr A C Dhariwal, head of India's National Vector Borne Disease Control Programme, said, &quot;It is the strain 2 that causes dengue hemorrhagic fever which is life-threatening. And this vaccine does not protect against this strain.&quot; Of the estimated 230 million people infected annually, two million &mdash; mostly children &mdash; develop dengue hemorrhagic fever (DHF), a severe form of the disease. According to Jean Lang, head of the vaccine's R&amp;D programme, largescale phase III clinical studies of the vaccine are presently under way on 31,000 adults and children in 10 countries &mdash; Mexico, Colombia, Honduras, Puerto Rico, Brazil, the Philippines, Vietnam, Malaysia, Indonesia and Thailand.&nbsp;</div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$reasonPhrase = 'OK'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitStatusLine() - CORE/src/Http/ResponseEmitter.php, line 148
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 54
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
Code Context
                    $value

                ), $first);

                $first = false;
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f105bc7fc66-trace').style.display = (document.getElementById('cakeErr67f105bc7fc66-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f105bc7fc66-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f105bc7fc66-code').style.display = (document.getElementById('cakeErr67f105bc7fc66-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f105bc7fc66-context').style.display = (document.getElementById('cakeErr67f105bc7fc66-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f105bc7fc66-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f105bc7fc66-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 18048,
		&#039;title&#039; =&gt; &#039;Vaccine against dengue to be tested in India -Kounteya Sinha&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div style=&quot;text-align: justify&quot;&gt;
-The Times of India
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;em&gt;PARIS:&lt;/em&gt; The world&#039;s most effective vaccine candidate against dengue is all set for trials in India and if all goes to plan, the vaccine will be available globally by 2015.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The vaccine will be tested on 120-odd adults in the beginning, the results of which should be available by 2013. Thereafter, a largescale study on children &amp;mdash; the main target group &amp;mdash; will be undertaken.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
In an exclusive interview, French pharma giant Sanofi Pasteur&#039;s CEO Christopher Viehbacher told TOI, &amp;quot;Sites for the vaccine&#039;s final trials will stretch from Thailand to India as this vaccine has to work on populations across countries. We will test it in India soon.&amp;quot;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Dr Jean Lang, head of the vaccine&#039;s R&amp;amp;D programme, added, &amp;quot;The drug controller general of India has asked us to conduct phase II safety trials on adults first, then on children. It will help us get licence to market the vaccine in India faster if it has been tested on the Indian population and is found safe and effective.&amp;quot;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;em&gt;Vaccine fights 3 of 4 dengue strains&lt;/em&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Even the world&#039;s most effective dengue vaccine candidate, set for trials in India soon, will not be able to counter all virus strains, early tests have showed.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
There is currently no vaccine to protect against dengue, and efforts to develop one have been hamstrung since four viruses (known as DENV 1, 2, 3 and 4) cause the disease. Researchers in France and Thailand recently announced that the vaccine under trials &amp;mdash; French pharma giant Sanofi Pasteur&#039;s CYD-TDV &amp;mdash; was tested for its effectiveness on a group of 4,002 schoolchildren in Thailand, aged four to eleven. Secondary tests showed that the vaccine was effective against DENV 1, 3 and 4 but not on DENV 2, which appeared to be resistant. The vaccine showed a 60-90% protection rate against three main virus strains (DENV 1, 3 and 4).
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&amp;quot;We are trying to find out why the vaccine wasn&#039;t very effective against the strain type 2,&amp;quot; said Sanofi&#039;s global R&amp;amp;D president Dr Elias Zerhouni. &amp;quot;We are also working on designing a separate vaccine to combat type 2 and a separate vaccine effective against the other three strains of dengue.&amp;quot;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Sources told TOI that a high-level meeting was held between scientists from Sanofi&#039;s dengue vaccine team and Indian experts, including former director general of the Indian Council of Medical Research Dr N K Ganguly, in New Delhi to discuss the India trials which will begins soon.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Dr A C Dhariwal, head of India&#039;s National Vector Borne Disease Control Programme, said, &amp;quot;It is the strain 2 that causes dengue hemorrhagic fever which is life-threatening. And this vaccine does not protect against this strain.&amp;quot; Of the estimated 230 million people infected annually, two million &amp;mdash; mostly children &amp;mdash; develop dengue hemorrhagic fever (DHF), a severe form of the disease. According to Jean Lang, head of the vaccine&#039;s R&amp;amp;D programme, largescale phase III clinical studies of the vaccine are presently under way on 31,000 adults and children in 10 countries &amp;mdash; Mexico, Colombia, Honduras, Puerto Rico, Brazil, the Philippines, Vietnam, Malaysia, Indonesia and Thailand.&amp;nbsp;
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Times of India, 19 November, 2012, http://timesofindia.indiatimes.com/home/science/Vaccine-against-dengue-to-be-tested-in-India/articleshow/17274153.cms&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;vaccine-against-dengue-to-be-tested-in-india-kounteya-sinha-18177&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 18177,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 18048,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Vaccine against dengue to be tested in India -Kounteya Sinha&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;dengue,Health,medicines&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Times of India





PARIS: The world&#039;s most effective vaccine candidate against dengue is all set for trials in India and if all goes to plan, the vaccine will be available globally by 2015.





The vaccine will be tested on 120-odd adults...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div style=&quot;text-align: justify&quot;&gt;-The Times of India&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;em&gt;PARIS:&lt;/em&gt; The world&#039;s most effective vaccine candidate against dengue is all set for trials in India and if all goes to plan, the vaccine will be available globally by 2015.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The vaccine will be tested on 120-odd adults in the beginning, the results of which should be available by 2013. Thereafter, a largescale study on children &amp;mdash; the main target group &amp;mdash; will be undertaken.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;In an exclusive interview, French pharma giant Sanofi Pasteur&#039;s CEO Christopher Viehbacher told TOI, &amp;quot;Sites for the vaccine&#039;s final trials will stretch from Thailand to India as this vaccine has to work on populations across countries. We will test it in India soon.&amp;quot;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Dr Jean Lang, head of the vaccine&#039;s R&amp;amp;D programme, added, &amp;quot;The drug controller general of India has asked us to conduct phase II safety trials on adults first, then on children. It will help us get licence to market the vaccine in India faster if it has been tested on the Indian population and is found safe and effective.&amp;quot;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;em&gt;Vaccine fights 3 of 4 dengue strains&lt;/em&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Even the world&#039;s most effective dengue vaccine candidate, set for trials in India soon, will not be able to counter all virus strains, early tests have showed.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;There is currently no vaccine to protect against dengue, and efforts to develop one have been hamstrung since four viruses (known as DENV 1, 2, 3 and 4) cause the disease. Researchers in France and Thailand recently announced that the vaccine under trials &amp;mdash; French pharma giant Sanofi Pasteur&#039;s CYD-TDV &amp;mdash; was tested for its effectiveness on a group of 4,002 schoolchildren in Thailand, aged four to eleven. Secondary tests showed that the vaccine was effective against DENV 1, 3 and 4 but not on DENV 2, which appeared to be resistant. The vaccine showed a 60-90% protection rate against three main virus strains (DENV 1, 3 and 4).&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&amp;quot;We are trying to find out why the vaccine wasn&#039;t very effective against the strain type 2,&amp;quot; said Sanofi&#039;s global R&amp;amp;D president Dr Elias Zerhouni. &amp;quot;We are also working on designing a separate vaccine to combat type 2 and a separate vaccine effective against the other three strains of dengue.&amp;quot;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Sources told TOI that a high-level meeting was held between scientists from Sanofi&#039;s dengue vaccine team and Indian experts, including former director general of the Indian Council of Medical Research Dr N K Ganguly, in New Delhi to discuss the India trials which will begins soon.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Dr A C Dhariwal, head of India&#039;s National Vector Borne Disease Control Programme, said, &amp;quot;It is the strain 2 that causes dengue hemorrhagic fever which is life-threatening. And this vaccine does not protect against this strain.&amp;quot; Of the estimated 230 million people infected annually, two million &amp;mdash; mostly children &amp;mdash; develop dengue hemorrhagic fever (DHF), a severe form of the disease. According to Jean Lang, head of the vaccine&#039;s R&amp;amp;D programme, largescale phase III clinical studies of the vaccine are presently under way on 31,000 adults and children in 10 countries &amp;mdash; Mexico, Colombia, Honduras, Puerto Rico, Brazil, the Philippines, Vietnam, Malaysia, Indonesia and Thailand.&amp;nbsp;&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 18048,
	&#039;title&#039; =&gt; &#039;Vaccine against dengue to be tested in India -Kounteya Sinha&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div style=&quot;text-align: justify&quot;&gt;
-The Times of India
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;em&gt;PARIS:&lt;/em&gt; The world&#039;s most effective vaccine candidate against dengue is all set for trials in India and if all goes to plan, the vaccine will be available globally by 2015.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The vaccine will be tested on 120-odd adults in the beginning, the results of which should be available by 2013. Thereafter, a largescale study on children &amp;mdash; the main target group &amp;mdash; will be undertaken.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
In an exclusive interview, French pharma giant Sanofi Pasteur&#039;s CEO Christopher Viehbacher told TOI, &amp;quot;Sites for the vaccine&#039;s final trials will stretch from Thailand to India as this vaccine has to work on populations across countries. We will test it in India soon.&amp;quot;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Dr Jean Lang, head of the vaccine&#039;s R&amp;amp;D programme, added, &amp;quot;The drug controller general of India has asked us to conduct phase II safety trials on adults first, then on children. It will help us get licence to market the vaccine in India faster if it has been tested on the Indian population and is found safe and effective.&amp;quot;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;em&gt;Vaccine fights 3 of 4 dengue strains&lt;/em&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Even the world&#039;s most effective dengue vaccine candidate, set for trials in India soon, will not be able to counter all virus strains, early tests have showed.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
There is currently no vaccine to protect against dengue, and efforts to develop one have been hamstrung since four viruses (known as DENV 1, 2, 3 and 4) cause the disease. Researchers in France and Thailand recently announced that the vaccine under trials &amp;mdash; French pharma giant Sanofi Pasteur&#039;s CYD-TDV &amp;mdash; was tested for its effectiveness on a group of 4,002 schoolchildren in Thailand, aged four to eleven. Secondary tests showed that the vaccine was effective against DENV 1, 3 and 4 but not on DENV 2, which appeared to be resistant. The vaccine showed a 60-90% protection rate against three main virus strains (DENV 1, 3 and 4).
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&amp;quot;We are trying to find out why the vaccine wasn&#039;t very effective against the strain type 2,&amp;quot; said Sanofi&#039;s global R&amp;amp;D president Dr Elias Zerhouni. &amp;quot;We are also working on designing a separate vaccine to combat type 2 and a separate vaccine effective against the other three strains of dengue.&amp;quot;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Sources told TOI that a high-level meeting was held between scientists from Sanofi&#039;s dengue vaccine team and Indian experts, including former director general of the Indian Council of Medical Research Dr N K Ganguly, in New Delhi to discuss the India trials which will begins soon.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Dr A C Dhariwal, head of India&#039;s National Vector Borne Disease Control Programme, said, &amp;quot;It is the strain 2 that causes dengue hemorrhagic fever which is life-threatening. And this vaccine does not protect against this strain.&amp;quot; Of the estimated 230 million people infected annually, two million &amp;mdash; mostly children &amp;mdash; develop dengue hemorrhagic fever (DHF), a severe form of the disease. According to Jean Lang, head of the vaccine&#039;s R&amp;amp;D programme, largescale phase III clinical studies of the vaccine are presently under way on 31,000 adults and children in 10 countries &amp;mdash; Mexico, Colombia, Honduras, Puerto Rico, Brazil, the Philippines, Vietnam, Malaysia, Indonesia and Thailand.&amp;nbsp;
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Times of India, 19 November, 2012, http://timesofindia.indiatimes.com/home/science/Vaccine-against-dengue-to-be-tested-in-India/articleshow/17274153.cms&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;vaccine-against-dengue-to-be-tested-in-india-kounteya-sinha-18177&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 18177,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 18048
$metaTitle = &#039;LATEST NEWS UPDATES | Vaccine against dengue to be tested in India -Kounteya Sinha&#039;
$metaKeywords = &#039;dengue,Health,medicines&#039;
$metaDesc = &#039;
-The Times of India





PARIS: The world&#039;s most effective vaccine candidate against dengue is all set for trials in India and if all goes to plan, the vaccine will be available globally by 2015.





The vaccine will be tested on 120-odd adults...&#039;
$disp = &#039;&lt;div style=&quot;text-align: justify&quot;&gt;-The Times of India&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;em&gt;PARIS:&lt;/em&gt; The world&#039;s most effective vaccine candidate against dengue is all set for trials in India and if all goes to plan, the vaccine will be available globally by 2015.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The vaccine will be tested on 120-odd adults in the beginning, the results of which should be available by 2013. Thereafter, a largescale study on children &amp;mdash; the main target group &amp;mdash; will be undertaken.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;In an exclusive interview, French pharma giant Sanofi Pasteur&#039;s CEO Christopher Viehbacher told TOI, &amp;quot;Sites for the vaccine&#039;s final trials will stretch from Thailand to India as this vaccine has to work on populations across countries. We will test it in India soon.&amp;quot;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Dr Jean Lang, head of the vaccine&#039;s R&amp;amp;D programme, added, &amp;quot;The drug controller general of India has asked us to conduct phase II safety trials on adults first, then on children. It will help us get licence to market the vaccine in India faster if it has been tested on the Indian population and is found safe and effective.&amp;quot;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;em&gt;Vaccine fights 3 of 4 dengue strains&lt;/em&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Even the world&#039;s most effective dengue vaccine candidate, set for trials in India soon, will not be able to counter all virus strains, early tests have showed.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;There is currently no vaccine to protect against dengue, and efforts to develop one have been hamstrung since four viruses (known as DENV 1, 2, 3 and 4) cause the disease. Researchers in France and Thailand recently announced that the vaccine under trials &amp;mdash; French pharma giant Sanofi Pasteur&#039;s CYD-TDV &amp;mdash; was tested for its effectiveness on a group of 4,002 schoolchildren in Thailand, aged four to eleven. Secondary tests showed that the vaccine was effective against DENV 1, 3 and 4 but not on DENV 2, which appeared to be resistant. The vaccine showed a 60-90% protection rate against three main virus strains (DENV 1, 3 and 4).&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&amp;quot;We are trying to find out why the vaccine wasn&#039;t very effective against the strain type 2,&amp;quot; said Sanofi&#039;s global R&amp;amp;D president Dr Elias Zerhouni. &amp;quot;We are also working on designing a separate vaccine to combat type 2 and a separate vaccine effective against the other three strains of dengue.&amp;quot;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Sources told TOI that a high-level meeting was held between scientists from Sanofi&#039;s dengue vaccine team and Indian experts, including former director general of the Indian Council of Medical Research Dr N K Ganguly, in New Delhi to discuss the India trials which will begins soon.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Dr A C Dhariwal, head of India&#039;s National Vector Borne Disease Control Programme, said, &amp;quot;It is the strain 2 that causes dengue hemorrhagic fever which is life-threatening. And this vaccine does not protect against this strain.&amp;quot; Of the estimated 230 million people infected annually, two million &amp;mdash; mostly children &amp;mdash; develop dengue hemorrhagic fever (DHF), a severe form of the disease. According to Jean Lang, head of the vaccine&#039;s R&amp;amp;D programme, largescale phase III clinical studies of the vaccine are presently under way on 31,000 adults and children in 10 countries &amp;mdash; Mexico, Colombia, Honduras, Puerto Rico, Brazil, the Philippines, Vietnam, Malaysia, Indonesia and Thailand.&amp;nbsp;&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/vaccine-against-dengue-to-be-tested-in-india-kounteya-sinha-18177.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Vaccine against dengue to be tested in India -Kounteya Sinha | Im4change.org</title>
    <meta name="description" content="
-The Times of India





PARIS: The world's most effective vaccine candidate against dengue is all set for trials in India and if all goes to plan, the vaccine will be available globally by 2015.





The vaccine will be tested on 120-odd adults..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Vaccine against dengue to be tested in India -Kounteya Sinha</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div style="text-align: justify">-The Times of India</div><div style="text-align: justify"><br /></div><div style="text-align: justify"><em>PARIS:</em> The world's most effective vaccine candidate against dengue is all set for trials in India and if all goes to plan, the vaccine will be available globally by 2015.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The vaccine will be tested on 120-odd adults in the beginning, the results of which should be available by 2013. Thereafter, a largescale study on children &mdash; the main target group &mdash; will be undertaken.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">In an exclusive interview, French pharma giant Sanofi Pasteur's CEO Christopher Viehbacher told TOI, &quot;Sites for the vaccine's final trials will stretch from Thailand to India as this vaccine has to work on populations across countries. We will test it in India soon.&quot;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">Dr Jean Lang, head of the vaccine's R&amp;D programme, added, &quot;The drug controller general of India has asked us to conduct phase II safety trials on adults first, then on children. It will help us get licence to market the vaccine in India faster if it has been tested on the Indian population and is found safe and effective.&quot;</div><div style="text-align: justify"><br /></div><div style="text-align: justify"><em>Vaccine fights 3 of 4 dengue strains</em></div><div style="text-align: justify"><br /></div><div style="text-align: justify">Even the world's most effective dengue vaccine candidate, set for trials in India soon, will not be able to counter all virus strains, early tests have showed.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">There is currently no vaccine to protect against dengue, and efforts to develop one have been hamstrung since four viruses (known as DENV 1, 2, 3 and 4) cause the disease. Researchers in France and Thailand recently announced that the vaccine under trials &mdash; French pharma giant Sanofi Pasteur's CYD-TDV &mdash; was tested for its effectiveness on a group of 4,002 schoolchildren in Thailand, aged four to eleven. Secondary tests showed that the vaccine was effective against DENV 1, 3 and 4 but not on DENV 2, which appeared to be resistant. The vaccine showed a 60-90% protection rate against three main virus strains (DENV 1, 3 and 4).</div><div style="text-align: justify"><br /></div><div style="text-align: justify">&quot;We are trying to find out why the vaccine wasn't very effective against the strain type 2,&quot; said Sanofi's global R&amp;D president Dr Elias Zerhouni. &quot;We are also working on designing a separate vaccine to combat type 2 and a separate vaccine effective against the other three strains of dengue.&quot;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">Sources told TOI that a high-level meeting was held between scientists from Sanofi's dengue vaccine team and Indian experts, including former director general of the Indian Council of Medical Research Dr N K Ganguly, in New Delhi to discuss the India trials which will begins soon.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">Dr A C Dhariwal, head of India's National Vector Borne Disease Control Programme, said, &quot;It is the strain 2 that causes dengue hemorrhagic fever which is life-threatening. And this vaccine does not protect against this strain.&quot; Of the estimated 230 million people infected annually, two million &mdash; mostly children &mdash; develop dengue hemorrhagic fever (DHF), a severe form of the disease. According to Jean Lang, head of the vaccine's R&amp;D programme, largescale phase III clinical studies of the vaccine are presently under way on 31,000 adults and children in 10 countries &mdash; Mexico, Colombia, Honduras, Puerto Rico, Brazil, the Philippines, Vietnam, Malaysia, Indonesia and Thailand.&nbsp;</div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$cookies = []
$values = [
	(int) 0 => 'text/html; charset=UTF-8'
]
$name = 'Content-Type'
$first = true
$value = 'text/html; charset=UTF-8'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitHeaders() - CORE/src/Http/ResponseEmitter.php, line 181
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 55
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

<head>

    <link rel="canonical" href="<?php echo Configure::read('SITE_URL'); ?><?php echo $urlPrefix;?><?php echo $article_current->category->slug; ?>/<?php echo $article_current->seo_url; ?>.html"/>

    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>

$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp'
$dataForView = [
	'article_current' => object(App\Model\Entity\Article) {

		'id' => (int) 18048,
		'title' => 'Vaccine against dengue to be tested in India -Kounteya Sinha',
		'subheading' => '',
		'description' => '<div style="text-align: justify">
-The Times of India
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
<em>PARIS:</em> The world's most effective vaccine candidate against dengue is all set for trials in India and if all goes to plan, the vaccine will be available globally by 2015.
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
The vaccine will be tested on 120-odd adults in the beginning, the results of which should be available by 2013. Thereafter, a largescale study on children &mdash; the main target group &mdash; will be undertaken.
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
In an exclusive interview, French pharma giant Sanofi Pasteur's CEO Christopher Viehbacher told TOI, &quot;Sites for the vaccine's final trials will stretch from Thailand to India as this vaccine has to work on populations across countries. We will test it in India soon.&quot;
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
Dr Jean Lang, head of the vaccine's R&amp;D programme, added, &quot;The drug controller general of India has asked us to conduct phase II safety trials on adults first, then on children. It will help us get licence to market the vaccine in India faster if it has been tested on the Indian population and is found safe and effective.&quot;
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
<em>Vaccine fights 3 of 4 dengue strains</em>
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
Even the world's most effective dengue vaccine candidate, set for trials in India soon, will not be able to counter all virus strains, early tests have showed.
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
There is currently no vaccine to protect against dengue, and efforts to develop one have been hamstrung since four viruses (known as DENV 1, 2, 3 and 4) cause the disease. Researchers in France and Thailand recently announced that the vaccine under trials &mdash; French pharma giant Sanofi Pasteur's CYD-TDV &mdash; was tested for its effectiveness on a group of 4,002 schoolchildren in Thailand, aged four to eleven. Secondary tests showed that the vaccine was effective against DENV 1, 3 and 4 but not on DENV 2, which appeared to be resistant. The vaccine showed a 60-90% protection rate against three main virus strains (DENV 1, 3 and 4).
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
&quot;We are trying to find out why the vaccine wasn't very effective against the strain type 2,&quot; said Sanofi's global R&amp;D president Dr Elias Zerhouni. &quot;We are also working on designing a separate vaccine to combat type 2 and a separate vaccine effective against the other three strains of dengue.&quot;
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
Sources told TOI that a high-level meeting was held between scientists from Sanofi's dengue vaccine team and Indian experts, including former director general of the Indian Council of Medical Research Dr N K Ganguly, in New Delhi to discuss the India trials which will begins soon.
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
Dr A C Dhariwal, head of India's National Vector Borne Disease Control Programme, said, &quot;It is the strain 2 that causes dengue hemorrhagic fever which is life-threatening. And this vaccine does not protect against this strain.&quot; Of the estimated 230 million people infected annually, two million &mdash; mostly children &mdash; develop dengue hemorrhagic fever (DHF), a severe form of the disease. According to Jean Lang, head of the vaccine's R&amp;D programme, largescale phase III clinical studies of the vaccine are presently under way on 31,000 adults and children in 10 countries &mdash; Mexico, Colombia, Honduras, Puerto Rico, Brazil, the Philippines, Vietnam, Malaysia, Indonesia and Thailand.&nbsp;
</div>',
		'credit_writer' => 'The Times of India, 19 November, 2012, http://timesofindia.indiatimes.com/home/science/Vaccine-against-dengue-to-be-tested-in-India/articleshow/17274153.cms',
		'article_img' => '',
		'article_img_thumb' => '',
		'status' => (int) 1,
		'show_on_home' => (int) 1,
		'lang' => 'EN',
		'category_id' => (int) 16,
		'tag_keyword' => '',
		'seo_url' => 'vaccine-against-dengue-to-be-tested-in-india-kounteya-sinha-18177',
		'meta_title' => null,
		'meta_keywords' => null,
		'meta_description' => null,
		'noindex' => (int) 0,
		'publish_date' => object(Cake\I18n\FrozenDate) {},
		'most_visit_section_id' => null,
		'article_big_img' => null,
		'liveid' => (int) 18177,
		'created' => object(Cake\I18n\FrozenTime) {},
		'modified' => object(Cake\I18n\FrozenTime) {},
		'edate' => '',
		'tags' => [
			[maximum depth reached]
		],
		'category' => object(App\Model\Entity\Category) {},
		'[new]' => false,
		'[accessible]' => [
			[maximum depth reached]
		],
		'[dirty]' => [[maximum depth reached]],
		'[original]' => [[maximum depth reached]],
		'[virtual]' => [[maximum depth reached]],
		'[hasErrors]' => false,
		'[errors]' => [[maximum depth reached]],
		'[invalid]' => [[maximum depth reached]],
		'[repository]' => 'Articles'
	
	},
	'articleid' => (int) 18048,
	'metaTitle' => 'LATEST NEWS UPDATES | Vaccine against dengue to be tested in India -Kounteya Sinha',
	'metaKeywords' => 'dengue,Health,medicines',
	'metaDesc' => '
-The Times of India





PARIS: The world's most effective vaccine candidate against dengue is all set for trials in India and if all goes to plan, the vaccine will be available globally by 2015.





The vaccine will be tested on 120-odd adults...',
	'disp' => '<div style="text-align: justify">-The Times of India</div><div style="text-align: justify"><br /></div><div style="text-align: justify"><em>PARIS:</em> The world's most effective vaccine candidate against dengue is all set for trials in India and if all goes to plan, the vaccine will be available globally by 2015.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The vaccine will be tested on 120-odd adults in the beginning, the results of which should be available by 2013. Thereafter, a largescale study on children &mdash; the main target group &mdash; will be undertaken.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">In an exclusive interview, French pharma giant Sanofi Pasteur's CEO Christopher Viehbacher told TOI, &quot;Sites for the vaccine's final trials will stretch from Thailand to India as this vaccine has to work on populations across countries. We will test it in India soon.&quot;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">Dr Jean Lang, head of the vaccine's R&amp;D programme, added, &quot;The drug controller general of India has asked us to conduct phase II safety trials on adults first, then on children. It will help us get licence to market the vaccine in India faster if it has been tested on the Indian population and is found safe and effective.&quot;</div><div style="text-align: justify"><br /></div><div style="text-align: justify"><em>Vaccine fights 3 of 4 dengue strains</em></div><div style="text-align: justify"><br /></div><div style="text-align: justify">Even the world's most effective dengue vaccine candidate, set for trials in India soon, will not be able to counter all virus strains, early tests have showed.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">There is currently no vaccine to protect against dengue, and efforts to develop one have been hamstrung since four viruses (known as DENV 1, 2, 3 and 4) cause the disease. Researchers in France and Thailand recently announced that the vaccine under trials &mdash; French pharma giant Sanofi Pasteur's CYD-TDV &mdash; was tested for its effectiveness on a group of 4,002 schoolchildren in Thailand, aged four to eleven. Secondary tests showed that the vaccine was effective against DENV 1, 3 and 4 but not on DENV 2, which appeared to be resistant. The vaccine showed a 60-90% protection rate against three main virus strains (DENV 1, 3 and 4).</div><div style="text-align: justify"><br /></div><div style="text-align: justify">&quot;We are trying to find out why the vaccine wasn't very effective against the strain type 2,&quot; said Sanofi's global R&amp;D president Dr Elias Zerhouni. &quot;We are also working on designing a separate vaccine to combat type 2 and a separate vaccine effective against the other three strains of dengue.&quot;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">Sources told TOI that a high-level meeting was held between scientists from Sanofi's dengue vaccine team and Indian experts, including former director general of the Indian Council of Medical Research Dr N K Ganguly, in New Delhi to discuss the India trials which will begins soon.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">Dr A C Dhariwal, head of India's National Vector Borne Disease Control Programme, said, &quot;It is the strain 2 that causes dengue hemorrhagic fever which is life-threatening. And this vaccine does not protect against this strain.&quot; Of the estimated 230 million people infected annually, two million &mdash; mostly children &mdash; develop dengue hemorrhagic fever (DHF), a severe form of the disease. According to Jean Lang, head of the vaccine's R&amp;D programme, largescale phase III clinical studies of the vaccine are presently under way on 31,000 adults and children in 10 countries &mdash; Mexico, Colombia, Honduras, Puerto Rico, Brazil, the Philippines, Vietnam, Malaysia, Indonesia and Thailand.&nbsp;</div>',
	'lang' => 'English',
	'SITE_URL' => 'https://im4change.in/',
	'site_title' => 'im4change',
	'adminprix' => 'admin'
]
$article_current = object(App\Model\Entity\Article) {

	'id' => (int) 18048,
	'title' => 'Vaccine against dengue to be tested in India -Kounteya Sinha',
	'subheading' => '',
	'description' => '<div style="text-align: justify">
-The Times of India
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
<em>PARIS:</em> The world's most effective vaccine candidate against dengue is all set for trials in India and if all goes to plan, the vaccine will be available globally by 2015.
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
The vaccine will be tested on 120-odd adults in the beginning, the results of which should be available by 2013. Thereafter, a largescale study on children &mdash; the main target group &mdash; will be undertaken.
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
In an exclusive interview, French pharma giant Sanofi Pasteur's CEO Christopher Viehbacher told TOI, &quot;Sites for the vaccine's final trials will stretch from Thailand to India as this vaccine has to work on populations across countries. We will test it in India soon.&quot;
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
Dr Jean Lang, head of the vaccine's R&amp;D programme, added, &quot;The drug controller general of India has asked us to conduct phase II safety trials on adults first, then on children. It will help us get licence to market the vaccine in India faster if it has been tested on the Indian population and is found safe and effective.&quot;
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
<em>Vaccine fights 3 of 4 dengue strains</em>
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
Even the world's most effective dengue vaccine candidate, set for trials in India soon, will not be able to counter all virus strains, early tests have showed.
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
There is currently no vaccine to protect against dengue, and efforts to develop one have been hamstrung since four viruses (known as DENV 1, 2, 3 and 4) cause the disease. Researchers in France and Thailand recently announced that the vaccine under trials &mdash; French pharma giant Sanofi Pasteur's CYD-TDV &mdash; was tested for its effectiveness on a group of 4,002 schoolchildren in Thailand, aged four to eleven. Secondary tests showed that the vaccine was effective against DENV 1, 3 and 4 but not on DENV 2, which appeared to be resistant. The vaccine showed a 60-90% protection rate against three main virus strains (DENV 1, 3 and 4).
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
&quot;We are trying to find out why the vaccine wasn't very effective against the strain type 2,&quot; said Sanofi's global R&amp;D president Dr Elias Zerhouni. &quot;We are also working on designing a separate vaccine to combat type 2 and a separate vaccine effective against the other three strains of dengue.&quot;
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
Sources told TOI that a high-level meeting was held between scientists from Sanofi's dengue vaccine team and Indian experts, including former director general of the Indian Council of Medical Research Dr N K Ganguly, in New Delhi to discuss the India trials which will begins soon.
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
Dr A C Dhariwal, head of India's National Vector Borne Disease Control Programme, said, &quot;It is the strain 2 that causes dengue hemorrhagic fever which is life-threatening. And this vaccine does not protect against this strain.&quot; Of the estimated 230 million people infected annually, two million &mdash; mostly children &mdash; develop dengue hemorrhagic fever (DHF), a severe form of the disease. According to Jean Lang, head of the vaccine's R&amp;D programme, largescale phase III clinical studies of the vaccine are presently under way on 31,000 adults and children in 10 countries &mdash; Mexico, Colombia, Honduras, Puerto Rico, Brazil, the Philippines, Vietnam, Malaysia, Indonesia and Thailand.&nbsp;
</div>',
	'credit_writer' => 'The Times of India, 19 November, 2012, http://timesofindia.indiatimes.com/home/science/Vaccine-against-dengue-to-be-tested-in-India/articleshow/17274153.cms',
	'article_img' => '',
	'article_img_thumb' => '',
	'status' => (int) 1,
	'show_on_home' => (int) 1,
	'lang' => 'EN',
	'category_id' => (int) 16,
	'tag_keyword' => '',
	'seo_url' => 'vaccine-against-dengue-to-be-tested-in-india-kounteya-sinha-18177',
	'meta_title' => null,
	'meta_keywords' => null,
	'meta_description' => null,
	'noindex' => (int) 0,
	'publish_date' => object(Cake\I18n\FrozenDate) {},
	'most_visit_section_id' => null,
	'article_big_img' => null,
	'liveid' => (int) 18177,
	'created' => object(Cake\I18n\FrozenTime) {},
	'modified' => object(Cake\I18n\FrozenTime) {},
	'edate' => '',
	'tags' => [
		(int) 0 => object(Cake\ORM\Entity) {},
		(int) 1 => object(Cake\ORM\Entity) {},
		(int) 2 => object(Cake\ORM\Entity) {}
	],
	'category' => object(App\Model\Entity\Category) {},
	'[new]' => false,
	'[accessible]' => [
		'*' => true,
		'id' => false
	],
	'[dirty]' => [],
	'[original]' => [],
	'[virtual]' => [],
	'[hasErrors]' => false,
	'[errors]' => [],
	'[invalid]' => [],
	'[repository]' => 'Articles'

}
$articleid = (int) 18048
$metaTitle = 'LATEST NEWS UPDATES | Vaccine against dengue to be tested in India -Kounteya Sinha'
$metaKeywords = 'dengue,Health,medicines'
$metaDesc = '
-The Times of India





PARIS: The world's most effective vaccine candidate against dengue is all set for trials in India and if all goes to plan, the vaccine will be available globally by 2015.





The vaccine will be tested on 120-odd adults...'
$disp = '<div style="text-align: justify">-The Times of India</div><div style="text-align: justify"><br /></div><div style="text-align: justify"><em>PARIS:</em> The world's most effective vaccine candidate against dengue is all set for trials in India and if all goes to plan, the vaccine will be available globally by 2015.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The vaccine will be tested on 120-odd adults in the beginning, the results of which should be available by 2013. Thereafter, a largescale study on children &mdash; the main target group &mdash; will be undertaken.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">In an exclusive interview, French pharma giant Sanofi Pasteur's CEO Christopher Viehbacher told TOI, &quot;Sites for the vaccine's final trials will stretch from Thailand to India as this vaccine has to work on populations across countries. We will test it in India soon.&quot;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">Dr Jean Lang, head of the vaccine's R&amp;D programme, added, &quot;The drug controller general of India has asked us to conduct phase II safety trials on adults first, then on children. It will help us get licence to market the vaccine in India faster if it has been tested on the Indian population and is found safe and effective.&quot;</div><div style="text-align: justify"><br /></div><div style="text-align: justify"><em>Vaccine fights 3 of 4 dengue strains</em></div><div style="text-align: justify"><br /></div><div style="text-align: justify">Even the world's most effective dengue vaccine candidate, set for trials in India soon, will not be able to counter all virus strains, early tests have showed.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">There is currently no vaccine to protect against dengue, and efforts to develop one have been hamstrung since four viruses (known as DENV 1, 2, 3 and 4) cause the disease. Researchers in France and Thailand recently announced that the vaccine under trials &mdash; French pharma giant Sanofi Pasteur's CYD-TDV &mdash; was tested for its effectiveness on a group of 4,002 schoolchildren in Thailand, aged four to eleven. Secondary tests showed that the vaccine was effective against DENV 1, 3 and 4 but not on DENV 2, which appeared to be resistant. The vaccine showed a 60-90% protection rate against three main virus strains (DENV 1, 3 and 4).</div><div style="text-align: justify"><br /></div><div style="text-align: justify">&quot;We are trying to find out why the vaccine wasn't very effective against the strain type 2,&quot; said Sanofi's global R&amp;D president Dr Elias Zerhouni. &quot;We are also working on designing a separate vaccine to combat type 2 and a separate vaccine effective against the other three strains of dengue.&quot;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">Sources told TOI that a high-level meeting was held between scientists from Sanofi's dengue vaccine team and Indian experts, including former director general of the Indian Council of Medical Research Dr N K Ganguly, in New Delhi to discuss the India trials which will begins soon.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">Dr A C Dhariwal, head of India's National Vector Borne Disease Control Programme, said, &quot;It is the strain 2 that causes dengue hemorrhagic fever which is life-threatening. And this vaccine does not protect against this strain.&quot; Of the estimated 230 million people infected annually, two million &mdash; mostly children &mdash; develop dengue hemorrhagic fever (DHF), a severe form of the disease. According to Jean Lang, head of the vaccine's R&amp;D programme, largescale phase III clinical studies of the vaccine are presently under way on 31,000 adults and children in 10 countries &mdash; Mexico, Colombia, Honduras, Puerto Rico, Brazil, the Philippines, Vietnam, Malaysia, Indonesia and Thailand.&nbsp;</div>'
$lang = 'English'
$SITE_URL = 'https://im4change.in/'
$site_title = 'im4change'
$adminprix = 'admin'

include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51

Vaccine against dengue to be tested in India -Kounteya Sinha

-The Times of India PARIS: The world's most effective vaccine candidate against dengue is all set for trials in India and if all goes to plan, the vaccine will be available globally by 2015. The vaccine will be tested on 120-odd adults in the beginning, the results of which should be available by 2013. Thereafter, a largescale study on children — the main target group — will be undertaken. In an exclusive interview, French pharma giant Sanofi Pasteur's CEO Christopher Viehbacher told TOI, "Sites for the vaccine's final trials will stretch from Thailand to India as this vaccine has to work on populations across countries. We will test it in India soon." Dr Jean Lang, head of the vaccine's R&D programme, added, "The drug controller general of India has asked us to conduct phase II safety trials on adults first, then on children. It will help us get licence to market the vaccine in India faster if it has been tested on the Indian population and is found safe and effective." Vaccine fights 3 of 4 dengue strains Even the world's most effective dengue vaccine candidate, set for trials in India soon, will not be able to counter all virus strains, early tests have showed. There is currently no vaccine to protect against dengue, and efforts to develop one have been hamstrung since four viruses (known as DENV 1, 2, 3 and 4) cause the disease. Researchers in France and Thailand recently announced that the vaccine under trials — French pharma giant Sanofi Pasteur's CYD-TDV — was tested for its effectiveness on a group of 4,002 schoolchildren in Thailand, aged four to eleven. Secondary tests showed that the vaccine was effective against DENV 1, 3 and 4 but not on DENV 2, which appeared to be resistant. The vaccine showed a 60-90% protection rate against three main virus strains (DENV 1, 3 and 4). "We are trying to find out why the vaccine wasn't very effective against the strain type 2," said Sanofi's global R&D president Dr Elias Zerhouni. "We are also working on designing a separate vaccine to combat type 2 and a separate vaccine effective against the other three strains of dengue." Sources told TOI that a high-level meeting was held between scientists from Sanofi's dengue vaccine team and Indian experts, including former director general of the Indian Council of Medical Research Dr N K Ganguly, in New Delhi to discuss the India trials which will begins soon. Dr A C Dhariwal, head of India's National Vector Borne Disease Control Programme, said, "It is the strain 2 that causes dengue hemorrhagic fever which is life-threatening. And this vaccine does not protect against this strain." Of the estimated 230 million people infected annually, two million — mostly children — develop dengue hemorrhagic fever (DHF), a severe form of the disease. According to Jean Lang, head of the vaccine's R&D programme, largescale phase III clinical studies of the vaccine are presently under way on 31,000 adults and children in 10 countries — Mexico, Colombia, Honduras, Puerto Rico, Brazil, the Philippines, Vietnam, Malaysia, Indonesia and Thailand.